Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,445.00
Bid: 1,435.00
Ask: 1,437.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.139%)
Open: 1,485.00
High: 1,485.00
Low: 1,410.00
Prev. Close: 1,445.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Q1 Results

7 Apr 2022 10:30

RNS Number : 6315H
Indivior PLC
07 April 2022
 

 

 

 

Indivior to Announce Q1 2022 Results and Host Webcast on April 28th

Slough, UK, and Richmond, VA, April 7, 2022 - Indivior PLC (LON: INDV) today announced that it will release its Q1 2022 results on April 28th at 12:00 GMT (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.

Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 13:00 GMT (8:00 a.m. U.S. Eastern) on April 28th.

Access to the Live Webcast Presentation

The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins.

The webcast link is https://edge.media-server.com/mmc/p/ogy6nn93.

Participants may access the presentation telephonically:

· US participants 1-646-741-3167

· International participants +44 (0) 2071-928338

 

Please reference confirmation ID 6687840. A replay of the presentation will be available at www.indivior.com.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com

 

Tim Owens

Director, Investor Relations

Tel: 804-263-3978 or timothy.owens@indivior.com

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORBKOBBFBKKDQK
Date   Source Headline
16th Sep 202210:46 amRNSHolding(s) in Company
16th Sep 20227:00 amRNSTransaction in Own Shares
15th Sep 20227:00 amRNSTransaction in Own Shares
14th Sep 20227:00 amRNSTransaction in Own Shares
13th Sep 20227:00 amRNSTransaction in Own Shares
12th Sep 20227:00 amRNSTransaction in Own Shares
9th Sep 20227:00 amRNSTransaction in Own Shares
8th Sep 20227:00 amRNSTransaction in Own Shares
7th Sep 20227:00 amRNSTransaction in Own Shares
6th Sep 20224:43 pmRNSIndivior to Participate in Investor Events
6th Sep 20222:49 pmRNSHolding(s) in Company
6th Sep 202211:46 amRNSHolding(s) in Company
6th Sep 20227:00 amRNSTransaction in Own Shares
5th Sep 202210:22 amRNSPublication of Circular and Notice of GM
5th Sep 20227:00 amRNSTransaction in Own Shares
2nd Sep 20229:24 amRNSHolding(s) in Company
2nd Sep 20227:00 amRNSTransaction in Own Shares
1st Sep 20229:44 amRNSTotal Voting Rights
1st Sep 20227:00 amRNSTransaction in Own Shares
31st Aug 20227:00 amRNSTransaction in Own Shares
30th Aug 20227:00 amRNSTransaction in Own Shares
26th Aug 20227:00 amRNSTransaction in Own Shares
25th Aug 202212:31 pmRNSHolding(s) in Company
25th Aug 20227:00 amRNSTransaction in Own Shares
24th Aug 20227:00 amRNSTransaction in Own Shares
23rd Aug 20227:00 amRNSTransaction in Own Shares
22nd Aug 20227:00 amRNSTransaction in Own Shares
19th Aug 20227:00 amRNSTransaction in Own Shares
18th Aug 20229:50 amRNSHolding(s) in Company
18th Aug 20227:00 amRNSTransaction in Own Shares
17th Aug 20227:00 amRNSTransaction in Own Shares
16th Aug 20227:00 amRNSTransaction in Own Shares
15th Aug 20227:00 amRNSTransaction in Own Shares
12th Aug 20227:00 amRNSTransaction in Own Shares
11th Aug 20227:00 amRNSTransaction in Own Shares
10th Aug 20227:00 amRNSTransaction in Own Shares
9th Aug 20227:00 amRNSTransaction in Own Shares
8th Aug 20227:00 amRNSTransaction in Own Shares
5th Aug 20227:00 amRNSTransaction in Own Shares
4th Aug 20222:30 pmRNSDirector/PDMR Shareholding
4th Aug 20227:00 amRNSTransaction in Own Shares
3rd Aug 20227:00 amRNSTransaction in Own Shares
2nd Aug 20227:00 amRNSTransaction in Own Shares
1st Aug 202211:00 amRNSTotal Voting Rights
1st Aug 20227:00 amRNSTransaction in Own Shares
29th Jul 20227:00 amRNSTransaction in Own Shares
28th Jul 20222:47 pmRNSHolding(s) in Company
28th Jul 20222:00 pmRNSBoard Committee Changes
28th Jul 20227:00 amRNSHalf-year Report
28th Jul 20227:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.